Cite
Sharma A, Shah M, Lakshmi S, et al. Corrigendum to "A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial" [Int. Immunopharmacol. 96 (2021) 107743]. Int Immunopharmacol. 2021;102:107932doi: 10.1016/j.intimp.2021.107932.
Sharma, A., Shah, M., Lakshmi, S., Sane, H., Captain, J., Gokulchandran, N., Khubchandani, P., Pradeep, M. K., Gote, P., Tuppekar, B., Kulkarni, P., Paranjape, A., Pradhan, R., Varghese, R., Kasekar, S., Nair, V., & Khanbande, U. (2022). Corrigendum to "A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial" [Int. Immunopharmacol. 96 (2021) 107743]. International immunopharmacology, 102107932. https://doi.org/10.1016/j.intimp.2021.107932
Sharma, Alok, et al. "Corrigendum to "A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial" [Int. Immunopharmacol. 96 (2021) 107743]." International immunopharmacology vol. 102 (2022): 107932. doi: https://doi.org/10.1016/j.intimp.2021.107932
Sharma A, Shah M, Lakshmi S, Sane H, Captain J, Gokulchandran N, Khubchandani P, Pradeep MK, Gote P, Tuppekar B, Kulkarni P, Paranjape A, Pradhan R, Varghese R, Kasekar S, Nair V, Khanbande U. Corrigendum to "A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial" [Int. Immunopharmacol. 96 (2021) 107743]. Int Immunopharmacol. 2022 Jan;102:107932. doi: 10.1016/j.intimp.2021.107932. Epub 2021 Jul 15. PMID: 34274220; PMCID: PMC8280341.
Copy
Download .nbib